-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$30.33115.72% Upside
Immunome, Inc. Frequently Asked Questions
-
What analysts cover Immunome, Inc.?
Immunome, Inc. has been rated by research analysts at Piper Sandler, Guggenheim, Wedbush in the past 90 days.